Novel Anti-Inflammatory-Pro-Resolving Mediators and their receptors

Current Topics in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 629-647

  Serhan, Charles N ^a   Krishnamoorthy, Sriram ^a   Recchiuti, Antonio ^a   Chiang, Nan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

G protein coupled receptor; inflammatory exudates; leukocytes; mediator lipidomics; omega 3 fatty acids; resolv ins

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTACOID; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; LIPOXIN; RECEPTOR BLOCKING AGENT;

ARTICLE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; HUMAN; INFLAMMATION; MEDIATOR; NONHUMAN;

EID: 79952941296     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026611109060629     Document Type: Article

References (119)

1. Serhan, C. N.; Clish, C. B.; Brannon, J.; Colgan, S. P.; Chiang, N.; Gronert, K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med., 2000, 192, 1197-1204.
2. Serhan, C. N.; Hong, S.; Gronert, K.; Colgan, S. P.; Devchand, P. R.; Mirick, G.; Moussignac, R.-L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med., 2002, 196, 1025-1037.
3. Serhan, C. N. Resolution phases of inflammation: novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu. Rev. Immunol., 2007, 25, 101-137.
4. Serhan, C. N.; Chiang, N.; Van Dyke, T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol., 2008, 8, 249-261.
5. Cotran, R. S.; Kumar, V.; Collins, T.; Eds. Robbins Pathologic Basis of Disease; W.B. Saunders Co. Philadelphia, 1999, p. 1425.
6. Majno, G.; Joris, I. Cells, Tissues, and Disease: Principles of General Pathology; Oxford University Press: New York, 2004, p. 1005.
7. Samuelsson, B.; Dahlen, S. E.; Lindgren, J. A.; Rouzer, C. A.; Serhan, C. N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science, 1987, 237, 1171-1176.
8. Van Dyke, T. E.; Serhan, C. N. A novel approach to resolving inflammation. Sci. Am. Oral Whole Body Health, 2006, 42-45.
9. Hansson, G. K.; Robertson, A. K. L.; Soderberg-Naucler, C. Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis., 2006,1, 297-329.
10. Serhan, C. N.; Savill, J. Resolution of inflammation: the beginning programs the end. Nat. Immunol., 2005, 6, 1191-1197.
11. Schwab, J. M.; Chiang, N.; Arita, M.; Serhan, C. N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 2007, 447, 869-874.
12. Serhan, C. N.; Yang, R.; Martinod, K.; Kasuga, K.; Pillai, P. S.; Porter, T. F.; Oh, S. F.; Spite, M. Maresins: novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J. Exp. Med., 2009, 206, 15-23.
13. Godson, C.; Mitchell, S.; Harvey, K.; Petasis, N. A.; Hogg, N.; Brady, H. R. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol., 2000, 164, 1663-1667.
14. Canny, G.; Levy, O.; Furuta, G. T.; Narravula-Alipati, S.; Sisson, R. B.; Serhan, C. N.; Colgan, S. P. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. USA, 2002, 99, 3902-3907.
15. Campbell, E. L.; Louis, N. A.; Tomassetti, S. E.; Canny, G. O.; Arita, M.; Serhan, C. N.; Colgan, S. P. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J., 2007, 21, 3162-3170.
16. [16] Serhan, C. N. guest ed. Special issue on lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids, 2005,73(3-4), 139-321.
17. Chiang, N.; Bermudez, E. A.; Ridker, P. M.; Hurwitz, S.; Serhan, C. N. Aspirin triggers anti-inflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA, 2004, 101, 15178-15183.
18. [18] Arita, M.; Bianchini, F.; Aliberti, J.; Sher, A.; Chiang, N.; Hong, S.; Yang, R.; Petasis, N. A.; Serhan, C. N. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med., 2005, 201, 713-722.
19. [19] Hong, S.; Gronert, K.; Devchand, P.; Moussignac, R.-L.; Serhan, C. N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem., 2003, 278, 14677-14687.
20. Serhan, C. N.; Gotlinger, K.; Hong, S.; Lu, Y.; Siegelman, J.; Baer, T.; Yang, R.; Colgan, S. P.; Petasis, N. A. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol., 2006, 176, 1848-1859.
21. Sun, Y.-P.; Oh, S. F.; Uddin, J.; Yang, R.; Gotlinger, K.; Campbell, E.; Colgan, S. P.; Petasis, N. A.; Serhan, C. N. Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, anti-inflammatory properties and enzymatic inactivation. J. Biol. Chem., 2007,282, 9323-9334.
22. Mukherjee, P. K.; Marcheselli, V. L.; Serhan, C. N.; Bazan, N. G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA, 2004, 101, 8491-8496.
23. Marcheselli, V. L.; Hong, S.; Lukiw, W. J.; Hua Tian, X.; Gronert, K.; Musto, A.; Hardy, M.; Gimenez, J. M.; Chiang, N.; Serhan, C. N.; Bazan, N. G. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem., 2003, 278, 43807-43817.
24. Gronert, K.; Maheshwari, N.; Khan, N.; Hassan, I. R.; Dunn, M.; Schwartzman, M. L. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem., 2005, 280, 15267-15278.
25. Bannenberg, G. L.; Chiang, N.; Ariel, A.; Arita, M.; Tjonahen, E.; Gotlinger, K. H.; Hong, S.; Serhan, C. N. Molecular circuits of resolution: Formation and actions of resolvins and protectins. J. Immunol., 2005, 174, 4345-4355.
26. Levy, B. D.; Clish, C. B.; Schmidt, B.; Gronert, K.; Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol., 2001, 2, 612-619.
27. Kasuga, K.; Yang, R.; Porter, T. F.; Agrawal, N.; Petasis, N. A.; Irimia, D.; Toner, M.; Serhan, C. N. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol., 2008, 181, 8677-8687.
28. Connor, K. M.; SanGiovanni, J. P.; Lofqvist, C.; Aderman, C. M.; Chen, J.; Higuchi, A.; Hong, S.; Pravda, E. A.; Majchrzak, S.; Carper, D.; Hellstrom, A.; Kang, J. X.; Chew, E. Y.; Salem, N. N., Jr.; Serhan, C. N.; Smith, L. E. H. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med., 2007, 13, 868-873.
29. Hudert, C. A.; Weylandt, K. H.; Wang, J.; Lu, Y.; Hong, S.; Dignass, A.; Serhan, C. N.; Kang, J. X. Transgenic mice rich in endogenous n-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA, 2006, 103, 11276-11281.
30. Poulsen, R. C.; Gotlinger, K. H.; Serhan, C. N.; Kruger, M. C. Identification of inflammatory and pro-resolving lipid mediators in bone marrow and their profile alteration with ovariectomy and omega-3 intake. Am. J. Hematol., 2008, 83, 437-445.
31. Arita, M.; Yoshida, M.; Hong, S.; Tjonahen, E.; Glickman, J. N.; Petasis, N. A.; Blumberg, R. S.; Serhan, C. N. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA, 2005, 102, 7671-7676.
32. Hasturk, H.; Kantarci, A.; Goguet-Surmenian, E.; Blackwood, A.; Andry, C.; Serhan, C. N.; Van Dyke, T. E. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis I. J. Immunol., 2007, 179, 7021-7029.
33. Chiang, N.; Serhan, C. N.; Dahlén, S.-E.; Drazen, J. M.; Hay, D. W. P.; Rovati, G. E.; Shimizu, T.; Yokomizo, T.; Brink, C. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions I. Pharmacol. Rev., 2006, 58, 463-487.
34. [34] McMahon, B.; Godson, C. Lipoxins: endogenous regulators of inflammation. Am. J. Physiol. Renal Physiol., 2004, 286, F189-F201.
35. Mitchell, D.; O'Meara, S. J.; Gaffney, A.; Crean, J. K.; Kinsella, B. T.; Godson, C. The lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases. J. Biol. Chem., 2007, 282, 15606-15618.
36. O'Sullivan, T. P.; Vallin, K. S.; Shah, S. T.; Fakhry, J.; Maderna, P.; Scannell, M.; Sampaio, A. L.; Perretti, M.; Godson, C.; Guiry, P. J. Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J. Med. Chem., 2007, 50, 5894-5902.
37. Reville, K.; Crean, J. K.; Vivers, S.; Dransfield, I.; Godson, C. Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J. Immunol., 2006,176, 1878-1888.
38. [38] Takano, T.; Clish, C. B.; Gronert, K.; Petasis, N.; Serhan, C. N. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest., 1998, 101, 819-826.
39. Takano, T.; Fiore, S.; Maddox, J. F.; Brady, H. R.; Petasis, N. A.; Serhan, C. N. Aspirin-triggered 15-epi-lipoxin A4 and LXA4 stable analogs are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med., 1997, 185, 1693-1704.
40. Colgan, S. P.; Serhan, C. N.; Parkos, C. A.; Delp-Archer, C.; Madara, J. L. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest., 1993,92, 75-82.
41. Kucharzik, T.; Gewirtz, A. T.; Merlin, D.; Madara, J. L.; Williams, I. R. Lateral membrane LXA4 receptors mediate LXA4's anti-inflammatory actions on intestinal epithelium. Am. J. Physiol. Cell Physiol., 2003, 284, C888-C896.
42. Brezinski, D. A.; Serhan, C. N. Characterization of lipoxins by combined gas chromatography and electron-capture negative ion chemical ionization mass spectrometry: formation of lipoxin A4 by stimulated human whole blood. Biol. Mass Spectrom., 1991, 20, 45-52.
43. Fiore, S.; Ryeom, S. W.; Weller, P. F.; Serhan, C. N. Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J. Biol. Chem., 1992, 267, 16168-16176.
44. Nigam, S.; Fiore, S.; Luscinskas, F. W.; Serhan, C. N. Lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils: dissociation between lipid remodeling and adhesion. J. Cell. Physiol., 1990, 143, 512-523.
45. Fiore, S.; Romano, M.; Reardon, E. M.; Serhan, C. N. Induction of functional lipoxin A4 receptors in HL-60 cells. Blood, 1993, 81, 3395-3403.
46. Ye, R. D.; Cavanagh, S. L.; Quehenberger, O.; Prossnitz, E. R.; Cocrane, C. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem. Biophys. Res. Commun., 1992,184, 582-589.
47. Ye, R. D.; Boulay, F.; Wang, J. M.; Dahlgren, C.; Gerard, C.; Parmentier, M.; Serhan, C. N.; Murphy, P. M. International Union of Basic and Clinical Pharmacology LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev., 2009, 61, 119-161.
48. Fiore, S.; Maddox, J. F.; Perez, H. D.; Serhan, C. N. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med., 1994, 180, 253-260.
49. Maddox, J. F.; Hachicha, M.; Takano, T.; Petasis, N. A.; Fokin, V. V.; Serhan, C. N. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein linked lipoxin A4 receptor. J. Biol. Chem., 1997, 272, 6972-6978.
50. Ariel, A.; Chiang, N.; Arita, M.; Petasis, N. A.; Serhan, C. N. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J. Immunol., 2003, 170, 6266-6272.
51. Sodin-Semrl, S.; Taddeo, B.; Tseng, D.; Varga, J.; Fiore, S. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol., 2000, 164, 2660-2666.
52. Gronert, K.; Gewirtz, A.; Madara, J. L.; Serhan, C. N. Identification of a human enterocyte lipoxin A4 receptor that is regulated by IL-13 and IFN-gamma and inhibits TNF-alpha-induced IL-8 release. J. Exp. Med., 1998, 187, 1285-1294.
53. Bao, L.; Gerard, N. P.; Eddy, R. L. Jr.; Shows, T. B.; Gerard, C. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan rceptors (FPRH1, FPRH2) to chromosome 19. Genomics, 1992, 13, 437-440.
54. [54] Serhan, C. N.; Maddox, J. F.; Petasis, N. A.; Akritopoulou-Zanze, I.; Papayianni, A.; Brady, H. R.; Colgan, S. P.; Madara, J. L. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry, 1995, 34, 14609-14615.
55. Serhan, C. N.; Fiore, S.; Brezinski, D. A.; Lynch, S. Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry, 1993,32, 6313-6319.
56. Clish, C. B.; Levy, B. D.; Chiang, N.; Tai, H.-H.; Serhan, C. N. Oxidoreductases in lipoxin A4 metabolic inactivation. J. Biol. Chem., 2000, 275, 25372-25380.
57. Fierro, I. M.; Colgan, S. P.; Bernasconi, G.; Petasis, N. A.; Clish, C. B.; Arita, M.; Serhan, C. N. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J. Immunol., 2003,170, 2688-2694.
58. Mills, J. S.; Miettinen, H. M.; Vlases, M. J.; Jesaitis, A. J. The N-formyl peptide receptor. In Molecular and Cellular Basis of Inflammation; Serhan, C. N.; Ward, P. A.; Eds.; Humana: Totowa, NJ, 1999, pp. 215-245.
59. Chiang, N.; Takano, T.; Arita, M.; Watanabe, S.; Serhan, C. N. A novel rat lipoxin A4 receptor that is conserved in structure and function. Br. J. Pharmacol., 2003, 139, 89-98.
60. Chiang, N.; Fierro, I. M.; Gronert, K.; Serhan, C. N. Activation of lipoxin A4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J. Exp. Med., 2000, 191, 1197-1207.
61. [61] Olofsson, S.; Khanna, B.; Lycke, E. Altered kinetic properties of sialyl and galactosyl transferases associated with herpes simplex virus infection of GMK and BHK cells. J. Gen. Virol., 1980, 47, 1-9.
62. Villanueva, M. S.; Beckers, C. J.; Pamer, E. G. Infection with Listeria monocytogenes impairs sialic acid addition to host cell glycoproteins. J. Exp. Med., 1994, 180, 2137-2145.
63. Kim, J. W.; Cunningham, J. M. N-linked glycosylation of the receptor for murine ecotropic retroviruses is altered in virus-infected cells. J. Biol. Chem., 1993, 268, 16316-16320.
64. Kang, Y.; Taddeo, B.; Varai, G.; Varga, J.; Fiore, S. Mutations of serine 235-237 and tyrosine 302 residues in the human lipoxin A4 receptor intracellular domains result in sustained signaling. Biochemistry, 2000, 39, 13551-13557.
65. Perretti, M.; Chiang, N.; La, M.; Fierro, I. M.; Marullo, S.; Getting, S. J.; Solito, E.; Serhan, C. N. Endogenous lipid-and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med., 2002,8, 1296-1302.
66. Cash, J. L.; Hart, R.; Russ, A.; Dixon, J. P. C.; Colledge, W. H.; Doran, J.; Hendrick, A. G.; Carlton, M. B. L.; Greaves, D. R. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med., 2008, 205, 767-775.
67. Devchand, P. R.; Arita, M.; Hong, S.; Bannenberg, G.; Moussignac, R.-L.; Gronert, K.; Serhan, C. N. Human ALX receptor regulates neutrophil recruitment in transgenic mice: Roles in inflammation and host-defense. FASEB J., 2003, 17, 652-659.
68. Levy, B. D.; De Sanctis, G. T.; Devchand, P. R.; Kim, E.; Ackerman, K.; Schmidt, B. A.; Szczeklik, W.; Drazen, J. M.; Serhan, C. N. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med., 2002, 8, 1018-1023.
69. Fukunaga, K.; Kohli, P.; Bonnans, C.; Fredenburgh, L. E.; Levy, B. D. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol., 2005, 174, 5033-5039.
70. Bürli, R. W.; Xu, H.; Zou, X.; Muller, K.; Golden, J.; Frohn, M.; Adlam, M.; Plant, M. H.; Wong, M.; McElvain, M.; Regal, K.; Viswanadhan, V. N.; Tagari, P.; Hungate, R. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett., 2006, 16, 3713-3718.
71. Frohn, M.; Xu, H.; Zou, X.; Chang, C.; McElvaine, M.; Plant, M. H.; Wong, M.; Tagari, P.; Hungate, R.; Bürli, R. W. New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation. Bioorg. Med. Chem. Lett., 2007, 17, 6633-6637.
72. Svensson, C. I.; Zattoni, M.; Serhan, C. N. Lipoxins and aspirin-triggered lipoxin stop inflammatory pain processing. J. Exp. Med., 2007,204, 245-252.
73. Gronert, K. Lipoxins in the eye and their role in wound healing. Prostaglandins Leukot. Essent. Fatty Acids, 2005, 73, 221-229.
74. Menezes-de-Lima, O., Jr.; Kassuya, C. A.; Nascimento, A. F.; Henriques, M. G.; Calixto, J. B. Lipoxin A4 inhibits edema in mice: Implications for the anti-edematogenic mechanism induced by aspirin. Prostaglandins Lipid Mediat., 2006, 80, 123-135.
75. Morris, T.; Stables, M.; Hobbs, A.; de Souza, P.; Colville-Nash, P.; Warner, T.; Newson, J.; Bellingan, G.; Gilroy, D. W. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol., 2009, 183, 2089-2096.
76. Jozsef, L.; Zouki, C.; Petasis, N. A.; Serhan, C. N.; Filep, J. G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. USA, 2002,99, 13266-13271.
77. Bannenberg, G.; Moussignac, R.-L.; Gronert, K.; Devchand, P.; Schmidt, B.; Guilford, W. J.; Bauman, J. G.; Subramanyam, B.; Perez, H. D.; Parkinson, J. F.; Serhan, C. N. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br. J. Pharmacol., 2004, 143, 43-52.
78. Damian, M.; Mary, S.; Martin, A.; Pin, J.-P.; Banères, J.-L. G protein activation by the leukotriene B4 receptor dimer: evidence for an absence of trans-activation. J. Biol. Chem., 2008, 283, 21084-21092.
79. Winyard, P. G.; Willoughby, D. A.; Eds. Inflammation Protocols; Humana: Totowa, NJ, 2003, p. 378.
80. Tessier, P. A.; Naccache, P. H.; Clark-Lewis, I.; Gladue, R. P.; Neote, K. S.; McColl, S. R. Chemokine networks I: involvement of C-X-C and C-C chemokines in neutrophil extravasation I in response to TNF-a. J. Immunol., 1997, 159, 3595-3602.
81. [81] McMahon, B.; Mitchell, S.; Brady, H. R.; Godson, C. Lipoxins: revelations on resolution. Trends Pharmacol. Sci., 2001, 22, 391-395.
82. Yokomizo, T.; Izumi, T.; Chang, K.; Takuwa, T.; Shimizu, T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature, 1997, 387, 620-624.
83. Gewirtz, A. T.; Collier-Hyams, L. S.; Young, A. N.; Kucharzik, T.; Guilford, W. J.; Parkinson, J. F.; Williams, I. R.; Neish, A. S.; Madara, J. L. Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol., 2002, 168, 5260-5267.
84. Samson, M.; Edinger, A. L.; Stordeur, P.; Rucker, J.; Verhasselt, V.; Sharron, M.; Govaerts, C.; Mollereau, C.; Vassart, G.; Doms, R. W.; Parmentier, M. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur. J. Immunol., 1998, 28, 1689-1700.
85. Kopp, E.; Ghosh, S. Inhibition of NF-kB by sodium salicylate and aspirin. Science, 1994, 265, 956-959.
86. Wittamer, V.; Franssen, J.; Vulcano, M.; Mirjolet, J.; Le Poul, E.; Migeotte, I.; Brezillon, S.; Tyldesley, R.; Blanpain, C.; Detheux, M.; Mantovani, A.; Sozzani, S.; Vassart, G.; Parmentier, M.; Communi, D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med., 2003, 198, 977-985.
87. Methner, A.; Hermey, G.; Schinke, B.; Hermans-Borgmeyer, I. A novel G protein-coupled receptor with homology to neuropeptide and chemoattractant receptors expressed during bone development. Biochem. Biophys. Res. Commun., 1997, 233, 336-342.
88. Endres, S.; Ghorbani, R.; Kelley, V. E.; Georgilis, K.; Lonnemann, G.; van der Meer, J. W.; Cannon, J. G.; Rogers, T. S.; Klempner, M. S.; Weber, P. C. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med., 1989, 320, 265-271.
89. Aliberti, J.; Hieny, S.; Reis e Sousa, C.; Serhan, C. N.; Sher, A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol., 2002,3, 76-82.
90. Yokomizo, T.; Kato, K.; Terawaki, K.; Izumi, T.; Shimizu, T. A second leukotriene B4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med., 2000, 192, 421-432.
91. Arita, M.; Ohira, T.; Sun, Y. P.; Elangovan, S.; Chiang, N.; Serhan, C. N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol., 2007, 178, 3912-3917.
92. Huang, L.; Zhao, A.; Wong, F.; Ayala, J. M.; Struthers, M.; Ujjainwalla, F.; Wright, S. D.; Springer, M. S.; Evans, J.; Cui, J. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler. Thromb. Vasc. Biol., 2004,24, 1783-1788.
93. Chiang, N.; Gronert, K.; Clish, C. B.; O'Brien, J. A.; Freeman, M. W.; Serhan, C. N. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest., 1999, 104, 309-316.
94. Gelman, S. The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology, 1995, 82, 1026-1060.
95. Qiu, F.-H.; Wada, K.; Stahl, G. L.; Serhan, C. N. IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. Proc. Natl. Acad. Sci. USA, 2000, 97, 4267-4272.
96. Arita, M.; Oh, S.; Chonan, T.; Hong, S.; Elangovan, S.; Sun, Y.-P.; Uddin, J.; Petasis, N. A.; Serhan, C. N. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem., 2006, 281, 22847-22854.
97. Hong, S.; Porter, T. F.; Lu, Y.; Oh, S. F.; Pillai, P. S.; Serhan, C. N. Resolvin E1 metabolome in local inactivation during inflammation-resolution. J. Immunol., 2008, 180, 3512-3519.
98. Jin, Y.; Arita, M.; Zhang, Q.; Saban, D. R.; Chauhan, S. K.; Chiang, N.; Serhan, C. N.; Dana, M. R. Novel anti-inflammatory and pro-resolving lipid mediators block inflammatory angiogenesis. Invest. Ophthalmol. Vis. Sci., 2009, 50, 4743-4752.
99. Merched, A.; Ko, K.; Gotlinger, K. H.; Serhan, C. N.; Chan, L. Atherosclerosis: Evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J., 2008,22, 3595-3606.
100. Barish, G. D.; Atkins, A. R.; Downes, M.; Olson, P.; Chong, L. W.; Nelson, M.; Zou, Y.; Hwang, H.; Kang, H.; Curtiss, L.; Evans, R. M.; Lee, C. H. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. USA, 2008,105, 4271-4276.
101. Serhan, C. N.; Chiang, N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol., 2008, 153 (Suppl. 1), S200-S215.
102. Krishnamoorthy, S.; Recchiuti, A.; Chiang, N.; Yacoubian, S.; Lee, C.-H.; Yang, R.; Petasis, N. A.; Serhan, C. N. Resolvin D1 binds human phagocytes with evidence for pro-resolving receptors. Proc. Natl. Acad. Sci. USA, 2010, 107, 1660-1665.
103. Naccache, P. H.; Faucher, N.; Therrien, S.; Borgeat, P. Calcium mobilization, actin polymerization and right-angle light scatter responses to leukotriene B4, 12(R)-and 12(S)-hydroxyeicosatetraenoic acid in human neutrophils. Life Sci., 1988, 42, 727-733.
104. Perretti, M.; D'Acquisto, F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol., 2009,9, 62-70.
105. Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 123-150.
106. Olson, K. R.; Eglen, R. M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev. Technol., 2007, 5, 137-144.
107. Duffield, J. S.; Hong, S.; Vaidya, V.; Lu, Y.; Fredman, G.; Serhan, C. N.; Bonventre, J. V. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol., 2006, 177, 5902-5911.
108. Perretti, M.; Getting, S. J.; Solito, E.; Murphy, P. M.; Gao, J. L. Am. J. Pathol., 2001, 158, 1969.
109. Marcheselli, V. L.; Mukherjee, P. K.; Arita, M.; Hong, S.; Antony, R.; Sheets, K.; Petasis, N.; Serhan, C. N.; Bazan, N. G. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fatty Acids, 2010, 82, 27-34.
110. Ishida, T.; Yoshida, M.; Arita, M.; Nishitani, Y.; Nishiumi, S.; Masuda, A.; Mizuno, S.; Takagawa, T.; Morita, Y.; Kutsumi, H.; Inokuchi, H.; Serhan, C. N.; Blumberg, R. S.; Azuma, T. Resolvin E1, an endogenous lipid derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis., 2010, 16, 87-95.
111. Dornelles, F. N.; Santos, D. S.; Van Dyke, T. E.; Calixto, J. B.; Batista, E. L., Jr.; Campos, M. M. I up-regulation of kinin B1 receptors after treatment with Porphyromonas gingivalis lipopolysaccharide in rat paw. J. Pharmacol. Exp. Ther., 2009, 330, 756-763.
112. González-Périz, A.; Horrillo, R.; Ferré, N.; Gronert, K.; Dong, B.; Morán-Salvador, E.; Titos, E.; Martínez-Clemente, M.; López-Parra, M.; Arroyo, V.; Clària, J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J., 2009, 23, 1946-1957.
113. Haworth, O.; Cernadas, M.; Yang, R.; Serhan, C. N.; Levy, B. D. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol., 2008, 9, 873-879.
114. Aoki, H.; Hisada, T.; Ishizuka, T.; Utsugi, M.; Kawata, T.; Shimizu, Y.; Okajima, F.; Dobashi, K.; Mori, M. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem. Biophys. Res. Commun., 2008, 367, 509-515.
115. Spite, M.; Summers, L.; Porter, T. F.; Srivastava, S.; Bhatnagar, A.; Serhan, C. N. Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Br. J. Pharmacol., 2009, 158, 1062-1073.
116. Ariel, A.; Li, P.-L.; Wang, W.; Tang, W.-X.; Fredman, G.; Hong, S.; Gotlinger, K. H.; Serhan, C. N. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem., 2005, 280, 43079-43086.
117. Levy, B. D.; Kohli, P.; Gotlinger, K.; Haworth, O.; Hong, S.; Kazani, S.; Israel, E.; Haley, K. J.; Serhan, C. N. Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J. Immunol., 2007, 178, 496-502.
118. Lukiw, W. J.; Cui, J. G.; Marcheselli, V. L.; Bodker, M.; Botkjaer, A.; Gotlinger, K.; Serhan, C. N.; Bazan, N. G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest., 2005, 115, 2774-2783.
119. Hassan, I. R.; Gronert, K. Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1. J. Immunol., 2009, 182, 3223-3232.